Full Text View
Tabular View
Study Results
Related Studies
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
This study has been terminated.
( change in development plan, not due to safety concerns. )
Study NCT00522457   Information provided by Fresenius Biotech GmbH

First Received on August 28, 2007.   Last Updated on April 28, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Metastatic Breast Cancer
Advanced Breast Cancer
Additional conditions recognized in this trial
Breast Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
ertumaxomab
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Trastuzumab
More general drug interventions related to this trial
Antineoplastic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Fresenius Biotech GmbH
Fresenius Biotech North America


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services